CIAM
LSTA icon

Caitong International Asset Management’s Lisata Therapeutics LSTA Stock Holding History

Caitong International Asset Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$110 Buy
+22
New +$91 ﹤0.01% 1956

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Caitong International Asset Management's LSTA Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Lisata Therapeutics (LSTA) in Q1 2026: 22 shares worth $110. The stake represents ﹤0.01% of the portfolio and ranks #1956 among its holdings.

34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • Caitong International Asset Management held 22 shares of Lisata Therapeutics worth $110 as of Q1 2026.
  • Lisata Therapeutics was a new Caitong International Asset Management position in Q1 2026.
  • Lisata Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1956 holding.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.